Download full-text PDF |
Source |
---|
Front Oncol
December 2024
Dermatological Department, Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital, Tianjin, China.
This study reports a 50-year-old patient presented with eczematous drug-eruption induced by selpercatinib after the treatment of non-small cell lung cancer (NSCLC). The patient has symmetric erythematous papules and plaques all over the body with dry, scaly skin accompanied by severe pruritus and visible scarring. After systemic treatment with glucocorticoids, the patient' skin lesions were reduced well.
View Article and Find Full Text PDFWe present a case of a patient with longstanding psoriasis vulgaris who developed an atopic dermatitis-like eruption following long-term IL-17A inhibitor therapy. Following many years of excellent disease control with secukinumab and later ixekizumab, he developed a de novo eczematous eruption, which showed spongiotic dermatitis upon biopsy. The patient was successfully treated for both psoriasis and atopic dermatitis with upadacitinib, a Janus kinase inhibitor.
View Article and Find Full Text PDFArch Dermatol Res
December 2024
Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napels, Italy.
Bimekizumab, is the most recent monoclonal antibody licensed for the management of moderate-to-severe plaque psoriasis, acting through the dual inhibition of interleukin (IL)-17 A and IL17F, setting it apart from other anti-IL17 biologics. To date, long-term data on the use of bimekizumab for the management of plaque psoriasis in a real-world setting are scant. The aim of our study was to evaluate the effectiveness and safety of bimekizumab in long-term.
View Article and Find Full Text PDFJ Cutan Med Surg
November 2024
Department of Dermatology, Venereology and Leprosy, Kasturba Medical College, Mangalore, Manipal Academy of Higher Education, Manipal, Karnataka, India.
Cureus
October 2024
Department of Dermatology, King Abdulaziz Hospital, Makkah, SAU.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!